Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years [Phase 3]

View source ↗

Summary

Phase 3 study evaluating SCT1000 for efficacy, safety, and immunogenicity in healthy women; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv Infection
• Hpv-related Carcinoma

Drugs mentioned

• SCT1000

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: HPV InfectioN, HPV-Related Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING